AOD-9604 Research Guide: hGH Fragment 176-191 & Lipolysis
AOD-9604 is a 16-amino-acid fragment of the C-terminus of human growth hormone, studied for its lipolytic effects without the metabolic side effects of full HGH.
What is AOD-9604?
AOD-9604 is a synthetic 16-amino-acid peptide based on the C-terminal lipolytic fragment of human growth hormone, residues 176-191. A tyrosine residue is added at the N-terminus to improve molecular stability.
It was developed in Australia at Monash University in the 1990s and originally investigated as an anti-obesity drug candidate.
Mechanism of action
Research suggests AOD-9604 reproduces the lipolytic activity of HGH — stimulating fat breakdown and inhibiting lipogenesis in adipocytes — without the receptor binding required for HGH's other systemic effects.
Notably, it does not raise IGF-1, does not affect insulin sensitivity or blood glucose, and does not promote longitudinal bone growth in animal models. The lipolytic activity appears mediated through beta-3 adrenergic receptor pathways rather than the GH receptor.
Compliance reminder
AOD-9604 is sold for laboratory research use only. Not for human consumption, diagnosis, treatment, or cure of any disease.
Frequently asked questions
What is AOD-9604?
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino-acid peptide corresponding to the C-terminal 176-191 region of human growth hormone, with a tyrosine residue added at the N-terminus for stability.
Mechanism?
The hGH(176-191) fragment carries the lipolytic activity of HGH without the receptor binding required for IGF-1 elevation or insulin-antagonist effects. It stimulates lipolysis and inhibits lipogenesis in adipose tissue research models.
How does it differ from HGH?
Unlike full HGH, AOD-9604 does not raise IGF-1, does not affect blood glucose, and does not bind the GH receptor with significant affinity. Its activity appears mediated by beta-3 adrenergic and other non-GHR pathways.